CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-11-28
DOI
10.3389/fimmu.2018.02722
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
- (2018) Esther Drent et al. PLoS One
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+
- (2018) F. Morandi et al. OncoImmunology
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu
- (2017) L Zhang et al. Blood Cancer Journal
- Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
- (2017) Federica Costa et al. Oncotarget
- Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
- (2017) Antonella Chillemi et al. Frontiers in Immunology
- Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo
- (2017) William Fumey et al. Scientific Reports
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
- (2016) Marije B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Immuno-targeting the multifunctional CD38 using nanobody
- (2016) Ting Li et al. Scientific Reports
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
- (2015) Wen-Chi Yang et al. Biomed Research International
- α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
- (2015) Katharina Teiluf et al. Oncotarget
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
- (2014) I. S. Nijhof et al. CLINICAL CANCER RESEARCH
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity
- (2013) A. Cagnetta et al. BLOOD
- A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
- (2013) D. J. Green et al. CANCER RESEARCH
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells
- (2011) K Mihara et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
- (2010) R A Kyle et al. LEUKEMIA
- Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse
- (2008) P. Munoz et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started